Lanthanum Carbonate — Membership Pricing

Other medications in Nephrology

• Patiromer
• Sevelamer
• Sodium Zirconium Cyclosilicate
• Sucroferric Oxyhydroxide

What Lanthanum Carbonate is approved for (FDA label)

LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: December 15, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Lanthanum Carbonate (FDA label)

LANTHANUM CARBONATE Chewable Tablets: 500 mg, 750 mg, and 1,000 mg. LANTHANUM CARBONATE Chewable Tablets: 500 mg, 750 mg, and 1,000 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: bb263fe8-2bdf-4dba-807f-194f54a73654. SPL document ID: bac21d2f-425d-46ab-ae15-e8cfb373615e. Label effective date: December 15, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Lanthanum Carbonate (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the labeling: Gastrointestinal Adverse Effects [see Warnings and Precautions (5.1) ] In controlled trials, the most common adverse reactions that were more frequent (≥5% difference vs. placebo) in LANTHANUM CARBONATE were nausea, vomiting, and abdominal pain. ( 6.1 ) The following adverse reactions have been identified during post-approval use of LANTHANUM CARBONATE: constipation, dyspepsia, allergic skin reactions, and tooth injury while chewing the tablet. ( 6.2 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-800-828-2088 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: bb263fe8-2bdf-4dba-807f-194f54a73654. SPL document ID: bac21d2f-425d-46ab-ae15-e8cfb373615e. Label effective date: December 15, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Lanthanum Carbonate (FDA label)

Contraindicated in patients with: - hypersensitivity to LANTHANUM CARBONATE or to any ingredient in the formulation. - bowel obstruction, including ileus and fecal impaction. Hypersensitivity to LANTHANUM CARBONATE or to any ingredient in the formulation. ( 4 ) Bowel obstruction, ileus, and fecal impaction. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: bb263fe8-2bdf-4dba-807f-194f54a73654. SPL document ID: bac21d2f-425d-46ab-ae15-e8cfb373615e. Label effective date: December 15, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Lanthanum Carbonate (FDA label)

Serious cases of gastrointestinal obstruction, ileus, subileus, gastrointestinal perforation, and fecal impaction. Risks include altered gastrointestinal anatomy, hypomotility disorders, and concomitant medications. Advise patients to chew or crush the tablet completely. ( 5.1 ) LANTHANUM CARBONATE has radio-opaque properties and, therefore, may give the appearance typical of an imaging agent during abdominal X-ray procedures. ( 5.2 ) 5.1 Gastrointestinal Adverse Effects Serious cases of gastrointestinal obstruction, ileus, subileus, gastrointestinal perforation, and fecal impaction have been reported in patients taking lanthanum, some requiring surgery or hospitalization. Consider discontinuing LANTHANUM CARBONATE in patients without another explanation for severe gastrointestinal symptoms.

Source: FDA prescribing information (DailyMed). Set ID: bb263fe8-2bdf-4dba-807f-194f54a73654. SPL document ID: bac21d2f-425d-46ab-ae15-e8cfb373615e. Label effective date: December 15, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Lanthanum Carbonate (FDA label)

There is a potential for LANTHANUM CARBONATE to interact with compounds that bind to cationic antacids (i.e., aluminum-, magnesium-, or calcium-based); therefore, do not take such compounds within 2 hours of dosing with LANTHANUM CARBONATE. ( 7.1 ) Oral quinolone antibiotics must be taken at least 1 hour before or 4 hours after LANTHANUM CARBONATE. ( 7.2 ) Do not take thyroid hormone replacement therapy within 2 hours of dosing with LANTHANUM CARBONATE. Monitoring of TSH levels is recommended in patients receiving both medicinal agents. ( 7.3 ) For oral medications where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, consider separation of the timing of the administration of the two drugs. ( 7.4 ) 7.1 Drugs Binding to Antacids There is a potential for LANTHANUM CARBONATE to interact with compounds which bind to cationic antacids (i.e., aluminum-, magnesium-,

Source: FDA prescribing information (DailyMed). Set ID: bb263fe8-2bdf-4dba-807f-194f54a73654. SPL document ID: bac21d2f-425d-46ab-ae15-e8cfb373615e. Label effective date: December 15, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.